SIBN
SI-BONE, Inc. · Healthcare · Medical - Devices
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 70 | -5 | 21.53M | $351.34M | +5 | −11 |
| Q1 2026 | 79 | +1 | 23.03M | $291.05M | +5 | −4 |
| Q4 2025 | 78 | 0 | 24.06M | $474.39M | — | — |
| Q3 2025 | 19 | +1 | 12.33M | $181.55M | +1 | — |
| Q2 2025 | 15 | +2 | 10.81M | $203.36M | +2 | — |
| Q1 2025 | 10 | +1 | 3.68M | $51.58M | +1 | — |
| Q4 2024 | 9 | +1 | 3.29M | $46.06M | +1 | — |
| Q3 2024 | 7 | -4 | 2.33M | $32.61M | — | −4 |
| Q2 2024 | 11 | — | 2.96M | $38.30M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 993.02K | — | $12.84M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 993.02K | — | $12.84M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 993.02K | — | $12.84M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 993.02K | — | $12.84M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 993.02K | — | $12.84M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 894.04K | — | $11.56M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 894.04K | — | $11.56M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Millennium Management ✦ | 239.95K | — | $3.10M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 231.87K | — | $3.00M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Marshall Wace ✦ | 208.69K | — | $2.70M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 208.69K | — | $2.70M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 156.95K | — | $2.03M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Renaissance Technologies ✦ | 130.70K | — | $1.69M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 31.86K | — | $412,002 | 0.0% | n/c | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 31.86K | — | $412,002 | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Bridgewater Associates ✦ | 30.86K | — | $398,994 | 0.0% | n/c | 1 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 28.06K | — | $363,000 | 0.0% | n/c | 1 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 15.79K | — | $204,229 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 178 holders, 43.26M shares, $537.87M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 11.23K sh · $224,785
Officer, Director · 3.92K sh · $78,538
Officer, Director · 51.88K sh · $1.01M
Officer · 5.75K sh · $112,354
Officer, Director · 2.24K sh · $41,772
Officer, Director · 1.97K sh · $36,755
Officer, Director · 3.89K sh · $72,616
Officer, Director · 3.65K sh · $68,144
Officer, Director · 3.20K sh · $59,778
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology